Donald Irby
Pfizer (United States)(US)
Publications by Year
Research Areas
Multiple Myeloma Research and Treatments, Hematopoietic Stem Cell Transplantation, RNA Interference and Gene Delivery, Statistical Methods in Clinical Trials, CAR-T cell therapy research
Most-Cited Works
- → Approaches to handling missing or “problematic” pharmacology data: Pharmacokinetics(2021)51 cited
- → Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans(2021)19 cited
- → Pharmacokinetic‐Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving High‐Dose Melphalan for Autologous Stem Cell Transplant(2018)16 cited
- → A Novel Two‐Part Mixture Model for the Incidence and Time Course of Cytokine Release Syndrome After Elranatamab Dosing in Multiple Myeloma Patients(2025)3 cited
- → P-315 Elranatamab exposure-safety analysis in patients with relapsed/refractory multiple myeloma: analysis from MagnetisMM studies(2023)2 cited
- → Clinical Factors Associated with Cytokine Release Syndrome and Dosing Recommendations for Restarting Elranatamab Following an Interruption(2023)2 cited
- → Dose Optimization of Elranatamab to Mitigate the Risk of Cytokine Release Syndrome in Patients with Multiple Myeloma(2025)2 cited
- → Automated Poisson regression exposure–response analysis for binary outcomes with PoissonERM(2024)1 cited
- → Comparison of Individualized Versus MAP-Bayesian Predicted AUC of Busulfan in FluBu4 Treated Patients Undergoing Allogeneic Transplant(2020)1 cited
- → Phase 1 Trial of AUC-Targeted Melphalan in Myeloma Patients Undergoing Autologous Transplant (The MyMel Study)(2022)